Today: 22 July 2026
Browse Category

NYSE:JNJ 19 December 2025 - 29 December 2025

For live price, interactive charts, financials and the latest market data, visit Google Finance.
Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

Johnson & Johnson stock heads into the final trading week of 2025 with U.S. markets shut for the weekend and investors sorting through a fresh pipeline headline that surfaced late Friday. With the New York Stock Exchange closed today and the next regular session set for Monday, Dec. 29, attention is shifting to what could move JNJ when trading resumes—including biotech read-throughs, litigation headlines, and year-end macro catalysts in a holiday-shortened week. New York Stock Exchange+2Investopedia+2
28 December 2025
··
Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson stock is heading into the final trading days of 2025 with U.S. markets closed for the weekend and year-end liquidity typically thinning across Wall Street. JNJ last closed at $207.63 on Friday, down 0.07% on the day, and was last indicated around $207.86 in after-hours trading, according to widely followed market data. Investing.com+1
27 December 2025
··
Johnson & Johnson (JNJ) Stock: What to Know Before the Market Opens on Dec. 26, 2025

Johnson & Johnson (JNJ) Stock: What to Know Before the Market Opens on Dec. 26, 2025

U.S. markets reopen for a full session on Friday, Dec. 26, 2025, following the Christmas Day closure—after a holiday-shortened early close on Wednesday, Dec. 24. New York Stock Exchange+1 For Johnson & Johnson investors, the post-holiday open comes with a familiar mix of defensive-stock appeal and headline risk—especially around talc litigation, Washington drug-pricing pressure, and the company’s portfolio reshaping plans.
26 December 2025
·
Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson is trading through a holiday-shortened Christmas Eve session with investors balancing a familiar mix of defensive appeal and headline risk. On Wednesday, December 24, 2025, J&J shares hovered around $207 in late-morning trade, keeping the healthcare bellwether close to its recent highs even as the company faces fresh legal scrutiny and renewed policy pressure on U.S. drug pricing. StockAnalysis
24 December 2025
···
Johnson & Johnson Stock After Hours Dec. 23, 2025: JNJ Slides on Record Talc Verdict — What to Know Before Wednesday’s Open

Johnson & Johnson Stock After Hours Dec. 23, 2025: JNJ Slides on Record Talc Verdict — What to Know Before Wednesday’s Open

Johnson & Johnson ended Tuesday’s session lower and traded narrowly after the closing bell as investors digested a fresh—and record-size—legal headline tied to the company’s long-running talc litigation. With U.S. markets heading into a holiday-shortened session on Wednesday, December 24, the near-term setup is as much about liquidity and headline risk as it is about fundamentals.
24 December 2025
·
Johnson & Johnson Stock (JNJ) Slips After Record $1.5B Talc Verdict: News, Forecasts, and What to Watch Into 2026

Johnson & Johnson Stock (JNJ) Slips After Record $1.5B Talc Verdict: News, Forecasts, and What to Watch Into 2026

Johnson & Johnson ended Tuesday, December 23, 2025, in the spotlight for reasons that cut both ways for investors: a headline-grabbing talc-related jury verdict that revived long-running legal risk concerns—and a steady drumbeat of regulatory and product updates that reinforce the company’s growth narrative across Innovative Medicine and MedTech.
23 December 2025
··
Johnson & Johnson (JNJ) Stock After Hours Today (Dec. 22, 2025): After-the-Bell Move, Key Headlines, and What to Watch Before Tuesday’s Open

Johnson & Johnson (JNJ) Stock After Hours Today (Dec. 22, 2025): After-the-Bell Move, Key Headlines, and What to Watch Before Tuesday’s Open

Johnson & Johnson ended Monday’s session modestly higher, and the stock’s after-hours action has been muted so far—typical for a mega-cap defensive name heading into a holiday-shortened week. Still, several active storylines are shaping sentiment tonight, including Washington’s drug-pricing push, fresh talc-litigation developments, and a steady stream of regulatory and pipeline updates that can influence the longer-term bull case.
23 December 2025
·
Johnson & Johnson Stock (JNJ) News Today: Latest Updates, Analyst Forecasts, and What Could Move Shares Next (Dec. 22, 2025)

Johnson & Johnson Stock (JNJ) News Today: Latest Updates, Analyst Forecasts, and What Could Move Shares Next (Dec. 22, 2025)

December 22, 2025 — Johnson & Johnson ends the year with momentum on its side, but not without familiar crosswinds. After a strong 2025 run, investors are balancing a string of late-year regulatory wins and product catalysts against ongoing talc-related litigation headlines—two forces that continue to shape near-term sentiment around Johnson & Johnson stock.
22 December 2025
·
Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

As the market heads into a Christmas-shortened trading week, Johnson & Johnson is entering the final stretch of 2025 with an unusually headline-heavy mix of catalysts: U.S. drug-pricing negotiations tied to the White House, new talc-related jury verdicts, and a string of FDA and clinical updates that reinforce the company’s longer-term growth narrative.
21 December 2025
··
1 … 4 5 6 7 8 9
Go toTop